P-153 Safety and effectiveness of sorafenib in elderly patients diagnosed with advanced hepatocellular carcinoma in a monographic oncologic center

Highlighting selected research conducted in older patients presented at the 23rd European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (2021): Young International Society of Geriatric Oncology Report

“…Sepulveda et al aimed to determine the impact of age, comorbidities, and initial dose reduction on the efficacy and safety of sorafenib among 202 older patients included in a retrospective analysis [3], where 23% (n = 45) of patients were ≥ 75 years. Over 90% of patients had an ECOG PS 0-1; no GA was performed.…”